Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Welcome to the last day of tax-loss selling ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jan 09, 2023 1:53pm
232 Views
Post# 35211604

RE:RE:RE:RE:RE:Welcome to the last day of tax-loss selling ...

RE:RE:RE:RE:RE:Welcome to the last day of tax-loss selling ...
davgro wrote:
Duster340 wrote: looks like you are the only one buying. i am sure the low 40's will come around again, i am waiting for the announcement of the start date for P2 before i buy. my guess  P2 will start last week of june. so plenty of time to get in. Q3 is in febuary maybe they will let us no the start date by then?

Low 40s again.....NOT !!

Nice buy Mugsy at C.44 even if it was just to average down.  My purchase of 20K shares recently at C.48 feels good.  I am hoping that today's run-up in the share price is sustained and not just an artificial spike.  Time will tell.

GLTA


IMO - 68 cents is the same at 47 cents - neither really matter to the potential of 2023.  Neither price makes sense but as investors, sometimes we have to live through these periods.

The longer the better in the 40s if we could have had it.

Anyway - looks like we might be at JPM this week (San Fran).  Don't care about any presentations but I'm hoping we're doing some one-on-ones there - building the partner base.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities